HC Wainwright Brokers Decrease Earnings Estimates for enGene

enGene Holdings Inc. (NASDAQ:ENGN) – Equities research analysts at HC Wainwright reduced their Q2 2025 earnings per share estimates for shares of enGene in a report issued on Tuesday, March 11th. HC Wainwright analyst A. Maldonado now expects that the company will post earnings of ($0.60) per share for the quarter, down from their prior estimate of ($0.44). HC Wainwright currently has a “Buy” rating and a $25.00 target price on the stock. The consensus estimate for enGene’s current full-year earnings is ($1.56) per share. HC Wainwright also issued estimates for enGene’s Q3 2025 earnings at ($0.63) EPS, Q4 2025 earnings at ($0.65) EPS, FY2026 earnings at ($2.16) EPS, FY2027 earnings at ($1.93) EPS, FY2028 earnings at ($0.96) EPS and FY2029 earnings at ($0.15) EPS.

enGene (NASDAQ:ENGN) last issued its quarterly earnings results on Thursday, December 19th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.06.

A number of other brokerages have also issued reports on ENGN. Piper Sandler started coverage on enGene in a research note on Tuesday, February 18th. They set an “overweight” rating and a $26.00 price target for the company. UBS Group lowered enGene from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $34.00 to $7.00 in a research note on Friday, February 14th. Morgan Stanley decreased their target price on enGene from $37.00 to $34.00 and set an “overweight” rating for the company in a research report on Tuesday. JMP Securities reaffirmed a “market outperform” rating and set a $18.00 target price on shares of enGene in a research report on Monday, December 23rd. Finally, Raymond James initiated coverage on enGene in a research report on Wednesday, November 27th. They set an “outperform” rating and a $23.00 target price for the company. One research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $25.22.

enGene Price Performance

Shares of ENGN stock opened at $5.35 on Thursday. enGene has a 52-week low of $4.42 and a 52-week high of $18.40. The company has a debt-to-equity ratio of 0.08, a quick ratio of 16.87 and a current ratio of 16.87. The firm has a market capitalization of $272.73 million, a P/E ratio of -9.22 and a beta of -0.61. The stock has a 50 day moving average price of $6.56 and a 200 day moving average price of $7.12.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the stock. Fcpm Iii Services B.V. raised its position in shares of enGene by 11.0% in the 4th quarter. Fcpm Iii Services B.V. now owns 9,632,561 shares of the company’s stock worth $64,057,000 after acquiring an additional 954,610 shares in the last quarter. VR Adviser LLC raised its position in shares of enGene by 41.5% in the 4th quarter. VR Adviser LLC now owns 5,046,414 shares of the company’s stock worth $33,559,000 after acquiring an additional 1,480,573 shares in the last quarter. Deep Track Capital LP raised its position in shares of enGene by 74.8% in the 4th quarter. Deep Track Capital LP now owns 4,557,575 shares of the company’s stock worth $30,308,000 after acquiring an additional 1,949,942 shares in the last quarter. Blue Owl Capital Holdings LP raised its position in shares of enGene by 3.3% in the 4th quarter. Blue Owl Capital Holdings LP now owns 3,159,975 shares of the company’s stock worth $21,014,000 after acquiring an additional 101,006 shares in the last quarter. Finally, Point72 Asset Management L.P. grew its stake in enGene by 84.7% during the 4th quarter. Point72 Asset Management L.P. now owns 1,224,797 shares of the company’s stock worth $8,145,000 after buying an additional 561,797 shares during the last quarter. 64.16% of the stock is owned by institutional investors.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.